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Survival differences between peritoneal dialysis and hemodial-
ysis among “large” ESRD patients in the United States.
Background. It has been hypothesized that peritoneal dialysis
compared to hemodialysis may be less effective in large patients
with end-stage renal disease (ESRD).
Methods. We tested this hypothesis in a cohort of 134,728
new ESRD patients who were initiated on dialysis from May
1, 1995 to July 31, 1997 using data from United States Renal
Data System (USRDS). Cox regression models evaluated the
association of body mass index (BMI) in quintiles (8.8–20.9,
20.9–23.5, 23.5–26.1, 26.1–30.0, 30.0–75.2 kg/m2) with mortality
over 2 years in peritoneal dialysis and hemodialysis patients
separately, while time-dependent models evaluated the relative
risk (RR) of death by modality for each BMI quintile.
Results. For hemodialysis, the adjusted RR of death was
greatest for patients with BMI ≤ 20.9 (RR = 1.40, 95% CI
1.32–1.50 for diabetics and RR = 1.27, 95% CI 1.21–1.34 for
nondiabetics) and lowest for patients with BMI >30.0 (RR =
0.97, 95% CI 0.96–0.99 for diabetic and RR = 0.97, 95% CI
0.95–0.98 for nondiabetic patients) compared with the referent
(23.5–26.1; RR = 1.00). For peritoneal dialysis, the RR of death
was also higher for patients with a BMI <20.9 (RR = 1.20, 95%
CI 1.00–1.43 for diabetic and RR = 1.39, 95% CI 1.19–1.64 for
nondiabetic patients) but no survival advantage was associated
with higher BMI values. The RR of death (peritoneal dialy-
sis/hemodialysis) for each BMI quintile was 0.99, 1.12, 1.26 (P <
0.01), 1.15 (P < 0.01), and 1.44 (P < 0.0001) for diabetic and
were 1.07, 1.01, 0.96, 1.04, and 1.22 (P < 0.01) for nondiabetic
patients, respectively.
Conclusion. We conclude that body size modifies the impact
of dialysis modality on mortality risk among new ESRD pa-
tients in the United States. The selection of hemodialysis over
peritoneal dialysiss was associated with a survival advantage in
patients with large body habitus.
The survival of dialysis patients who reach end-stage re-
nal disease (ESRD) has not improved substantially over
the last decade despite tremendous advances in dialysis
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technology and considerable improvements in the deliv-
ery of health care [1]. Although, renal transplantation
offers the best hope to patients with ESRD, only a small
fraction of the incident ESRD population in the United
States will get that opportunity, leaving the majority to
receive either hemodialysis or peritoneal dialysis [1, 2].
For these patients, defining the optimal modality strategy
at ESRD onset is a critical component of patient manage-
ment to ensure optimal survival. While some may view
peritoneal dialysis and hemodialysis as “complementary”
therapies and have advocated peritoneal dialysis as the
modality of first choice for all new ESRD patients, oth-
ers have questioned this “integrated care concept” hav-
ing found significantly greater mortality rates among new
ESRD patients with cardiovascular disease when peri-
toneal dialysis was used as the first line therapy [3–6].
Accordingly, defining the optimal modality strategy for
high-risk populations at ESRD onset is an important task
and has been advocated by the National Kidney Founda-
tion (NKF) Kidney Disease Outcomes Quality Initiative
(K/DOQI) committee [7].
The optimal management of patients with ESRD and
large body habitus is a challenging problem for all
members of the chronic kidney disease team [7, 8]. It
has recently been suggested that large patients treated
with peritoneal dialysis may have difficulty in achiev-
ing adequate dialysis as measured by Kt/Vurea based on
currently recommended K/DOQI guidelines. This may
become especially apparent when residual renal function
falls over time. These difficulties in achieving adequate
solute clearance have also been predicted in mathemat-
ical models evaluating dialysis delivery as a function of
body size [9]. Similarly, the provision of adequate dialysis
may be equally challenging for large patients treated with
hemodialysis [10]. Recent studies have demonstrated a
greater likelihood of underdialysis among patients with
increasing body weight [10, 11]. It is unclear from ex-
isting studies, therefore, whether peritoneal dialysis or
hemodialysis may offer the best therapeutic approach to
the management of new ESRD patients with large body
habitus. A further complicating factor is the observation
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that survival of patients with large body habitus under-
going chronic dialysis is significantly greater than those
with smaller body frames [12–15]. This survival bene-
fit has been attributed, at least in part, to greater en-
ergy storage reserve among large patients. The aim of
the present study, therefore, was to determine whether
peritoneal dialysis as compared to hemodialysis offers a
greater survival benefit for new ESRD patients with large
body habitus. This was based on the hypothesis that body
mass index (BMI) modifies the impact of dialysis treat-
ment modality on survival.
METHODS
Data source
This study was a historical prospective cohort of new
ESRD patients in the United States who were initiated
on dialysis between May 1, 1995 and July 31, 1997. Avail-
able data on patients’ characteristics and mortality for
the proposed analysis were obtained form the United
States Renal Data System (USRDS) Standard Analy-
sis Files (SAF) [1]. The Medical Evidence SAF served
as the source file for incident data on all new ESRD pa-
tients who were initiated on dialysis during this period
and is based on the Center for Medicare and Medicaid
Services (CMS) Medical Evidence Form, a government
document that is completed for all new patients initi-
ated on dialysis in the United States [16]. The CMS form
records data on demographic characteristics, comorbid
conditions, laboratory indices, date of first dialysis and
type of treatment provided for all incident patients. In
addition, data were also available for the following an-
thropometric; weight and height, and laboratory indices;
serum creatinine, blood urea nitrogen, serum albumin,
and hematocrit.
The Treatment History SAF of the USRDS served as
the main source of data to characterize the type of dialysis
modality that was used for each patient during follow-up.
The USRDS determines the treatment modality for each
new ESRD patient in the United States from a variety of
data sources using complex analytical approach. These
data sources include the Medical Evidence Form, the
Quarterly Dialysis File, and the Medicare Claims Files.
Treatment modality, hemodialysis or peritoneal dialysis
for each patient was determined from the USRDS [1].
Switches in treatment modality, from hemodialysis to
peritoneal dialysis or peritoneal dialysis to hemodialy-
sis, during follow-up are recorded in the data files and
can be used to define the total period for which patients
remained on a specific therapy. The definition of switch
was based on the 60-day rule as suggested by the USRDS.
This rule requires that a patient be on a new modality for
at least 60 days before it is considered to be a change in
modality [1]. The study start date for all incident patients
was defined as day 90 of ESRD. The Medical Evidence
and Treatment History datasets were merged with mor-
tality and transplantation data from the USRDS. This
allowed merging of data on date of death and date of re-
nal transplantation by USRDS identification number for
each member of the study.
Patient population
There were 158,685 patients, age 18 and over, who were
initiated on dialysis from May 1, 1995 to July 31, 1997.
Patients were excluded from the analysis; if they had re-
ceived a renal transplant within the first 90 days of ESRD
initiation (N = 2890), if modality assignment could not be
determined at day 90 of ESRD (N = 4151), if their BMI
could not be ascertained at ESRD onset (N = 4958) (i.e.,
missing data on height or weight measures) or if they had
died within the first 90 days (N = 11,958). Following these
exclusions, there were 134,728 adult patients available for
this analysis.
Analytical methods
BMI was computed from an individuals weight in kilo-
grams divided by the square of their height in meters
(BMI = weight (kg)/height (m2) and the BMI values
for the entire cohort were categorized in quintile groups.
The chi-square and analysis of variance (ANOVA) mod-
els were used to test for differences among groups. Cox
proportional hazards regression was used to evaluate the
association of BMI in quintiles with mortality in peri-
toneal dialysis and hemodialysis patients separately with
adjustment for case mix. Time-dependent Cox regression
equations compared the mortality risks of hemodialy-
sis with peritoneal dialysis in each quintile group with
adjustment for potential confounders. Covariates for
adjustment included age at study start (modeled as a con-
tinuous variable), gender (male vs. female), race (white
vs. nonwhite race), hypertension, congestive heart fail-
ure, coronary artery disease (defined as a history of prior
coronary artery disease, myocardial infarction, angio-
plasty, or coronary artery bypass graft), peripheral vas-
cular and cerebrovascular disease (defined as a history
of prior cerebrovascular accident or transient ischemic
attack), tobacco use, chronic obstructive lung disease,
history of cardiac arrest/arrhythmia, acquired immunod-
eficiency syndrome (AIDS), neoplasm, serum albumin,
hematocrit, estimated glomerular filtration rate, and pre-
ESRD erythropoietin use and a measure of functional
status (ability to walk or transfer without assistance).
Residual renal function at ESRD initiation was estimated
from the Modification of Diet in Renal Disease (MDRD)
formula [17]. Diabetics and nondiabetic were analyzed in
separate models on finding the presence of nonpropor-
tional hazards. An interaction term (BMI ∗ peritoneal
dialysis) was included in each of the main models to
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determine whether BMI modified the impact of a spe-
cific treatment modality on survival.
Patient survival times on peritoneal dialysis and
hemodialysis were compared at successive 6-month in-
tervals during follow-up and censored at death, trans-
plantation, loss to follow-up, or at the end of 2 years
whichever came first. “Intent-to-treat” and “as-treated”
models evaluated the association of treatment modality
with mortality risk in each BMI quintile. In the “intent-
to-treat” analyses, patients were not censored if they
changed treatment modality during follow-up and patient
death was assigned to the initial treatment modality. In
the “as-treated” analyses, patients were censored from
contributing additional time at risk when they switched
from one modality of treatment to another. In these se-
ries of models, a lag time of 60 days was allowed before
assigning death to the new modality. Thus deaths occur-
ring within 60 days after the switch were assigned to
the original modality while deaths occurring thereafter
were assigned to the new modality. This methodology
was in keeping with previous published comparisons and
takes into consideration the fact that deaths occurring
immediately after a switch in therapy may in fact be a
consequence of the switch rather than a consequence
of the new therapy. Moreover, the as-treated analysis
evaluated mortality risks of patients who switched from
one modality to another during the follow-up period by
comparing survival times of patients who switched from
peritoneal dialysis to hemodialysis (hemodialysisnew) and
from hemodialysis to peritoneal dialysis (peritoneal dial-
ysisnew) with those remaining on peritoneal dialysis (peri-
toneal dialysisold) or hemodialysis (hemodialysisold) since
ESRD start. No attempt was made to impute values for
missing data and therefore the final multivariable mod-
els were restricted to a cohort of 101,081 patients with
complete data on all variables. Statistical analyses were
performed using SAS Statistical Software (version 8.0)
(SAS Institute, Cary, NC, USA).
RESULTS
Baseline characteristics of the study cohort
The study cohort consisted of 134,728 patients who
were initiated on dialysis between May 1, 1995 and July
31, 1997 and survived 90 days after dialysis initiation.
Table 1 illustrates the characteristics of the entire cohort
at study entry. The average age at onset of ESRD was
61.5 ± 15 years, 63% were white, 53% were male, and
44% had diabetes recorded as the cause of ESRD. The
prevalence of comorbid clinical conditions at ESRD on-
set was substantial with 50.2% having diabetes, 72% hy-
pertension, 26% coronary artery disease, 32.4% conges-
tive heart failure, and 14.3% peripheral vascular disease.
The average serum albumin, hematocrit, and serum cre-
atinine values for the entire population were 3.2 ± 0.66
Table 1. Characteristics of the study population at end-stage renal
disease (ESRD) onset from the Center for Medicare and Medicaid
Services (CMS) Medical Evidence Report Form
Study
Patient characteristics population
N = 134,728
Demographics
Age of onset of end-stage renal disease 61.5 ± 15.3
(ESRD) years
Race
% white 63.3
% black 31.3
% Asian 3.7
Gender (% male) 53.0
Cause of ESRD% diabetes 44.1
Laboratory values
Serum albumin (N = 110,459) g/dL 3.2 ± 0.66
Hematocrit (N = 127,195)% 28.1 ± 5.3
Serum creatinine (N = 132,426) mg/dL 8.6 ± 3.9
Glomerular filtration rate (N = 103,383) 7.0 ± 2.8
mL/mina
Comorbid conditions (% yes)
Diabetes (as a cause of ESRD or 50.2
comorbid condition)
Hypertension 71.9
Coronary artery diseaseb 25.5
Myocardial infarction 8.8
Cardiac arrest/dysrhythmia 6.2
Congestive heart failure 32.4
Cerebrovascular disease 8.8
Peripheral vascular diseasec 14.3
Chronic obstructive lung disease 6.8
Tobacco use 6.1
AIDS 0.6
Neoplasm 4.8
Alcohol dependence 1.9
Body mass index (BMI) kg/m2 25.7 ± 5.8
Functional status (% yes)
Unable to walk 4.3
Unable to transfer 1.4
Pre-ESRD care (%yes)
Erythropoietin use 23.3
Treatment modality
Peritoneal dialysis 13
Hemodialysis 87
aAt first dialysis per MDRD formula [17]; bIncludes history of coronary
artery disease, myocardial infarction, coronary artery bypass surgery, angioplasty
or abnormal angiography; cIncludes a history of peripheral vascular disease
amputation, intermittent claudication or absent pulses.
g/dL, 28.1 ± 5.3% and 8.6 ± 3.9 mg/dL, respectively, and
the estimated mean glomerular filtration rate was 7.0 ±
2.8 mL/min. Hemodialysis was the initial dialysis modal-
ity for 117,309 (87.1%) and peritoneal dialysis for 17,419
(13%). The demographic and clinical characteristics of
patients excluded from this analysis as a result of miss-
ing data on modality assignment were nearly identical to
those of the study population.
BMI at ESRD initiation
The mean BMI of the entire population was 25.7 kg/m2
with a SD of 5.8 kg/m2. The characteristics of patients in
each BMI quintile group and the percentage of patients
treated with either peritoneal dialysis or hemodialysis are
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Table 2. Characteristics of the study population at end-stage renal disease (ESRD) onset from the Center for Medicare and Medicaid Services
(CMS) Medical Evidence Report Form by body mass index (BMI) quintile (N = 134,728)
Patient characteristics BMI-1 BMI-2 BMI-3 BMI-4 BMI-5
(8.8–20.9) (20.9–23.5) (23.5–26.1) (26.1–30.0) (30.0–75.2)
Number of patients 27,197 26,691 26,860 27,020 26,960
Demographics
Age of onset of ESRDa years 62.9 ± 17.1 62.4 ± 16.3 62.3 ± 15.2 61.3 ± 14.1 58.6 ± 13.3
Race
% whitea 62.5 66.1 65.7 63.9 58.4
% blacka 29.9 28.2 29.1 31.6 37.6
% Asiana 6.2 4.3 3.5 2.4 1.9
Gender (% male)a 50.5 58.7 59.8 55.4 40.5
Cause of ESRD (% diabetes)a 28.0 34.5 38.7 43.8 49.6
Laboratory values
Serum albumin g/dLa 3.16 ± 0.67 3.21 ± 0.66 3.25 ± 0.66 3.25 ± 0.65 3.23 ± 0.64
Hematocrit %a 27.9 ± 5.6 28.1 ± 5.4 28.1 ± 5.3 28.2 ± 5.2 28.1 ± 5.1
Glomerular filtration rate mL/mina,b 7.3 ± 3.0 7.1 ± 2.8 7.0 ± 2.8 6.9 ± 2.8 6.8 ± 2.7
Comorbid conditions (% yes)
Diabetes (cause of ESRD or comorbidity)a 35.7 44.1 49.8 56.6 65.0
Hypertensiona 68.8 70.7 71.8 73.1 74.9
Coronary artery diseasea,c 25.1 26.7 26.6 26.0 23.4
Myocardial infarctiona 8.7 9.4 9.4 8.8 7.6
Cardiac arrest/dysrhythmiaa 7.1 6.8 6.2 5.9 5.0
Congestive heart failured 33.0 32.0 31.8 32.0 33.0
Cerebrovascular diseasea 10.3 9.2 9.0 8.4 7.1
Peripheral vascular diseasea,e 15.6 15.0 14.6 13.6 12.7
Chronic obstructive lung diseasea 9.7 7.1 5.8 5.6 5.5
Tobacco usea 8.5 6.9 5.7 5.2 3.9
AIDSa 1.14 0.68 0.47 0.27 0.17
Neoplasma 5.5 5.2 5.1 4.6 3.8
Alcohol dependencea 3.0 2.1 1.8 1.6 1.0
BMI kg/m2a 18.9 ± 1.6 22.2 ± 0.7 24.7 ± 0.8 27.9 ± 1.1 34.7 ± 4.3
Peritoneal dialysis patientsa 19.1 ± 1.5 22.3 ± 0.7 24.7 ± 0.8 27.8 ± 1.1 34.2 ± 3.9
Hemodialysis patientsa 18.9 + 1.6 22.2 + 0.7 24.7 + 0.8 27.9 + 1.1 34.7 + 4.3
Functional status (% yes)
Unable to walka 5.8 4.0 3.6 3.6 4.4
Unable to transfera 2.0 1.4 1.2 1.1 1.4
Pre-ESRD care (% yes)
Erythropoietin usea 22.4 23.8 23.9 23.4 22.8
Treatment modality
Peritoneal dialysisa 10.0 13.3 14.4 14.4 12.6
Hemodialysisa 90.0 86.7 85.6 85.6 87.4
aP < 0.001 for group comparisons; bAt first dialysis per MDRD formula [17]; cIncludes history of coronary artery disease, myocardial infarction, coronary artery
bypass surgery, angioplasty or abnormal angiography; dP < 0.01; eIncludes a history of peripheral vascular disease amputation, intermittent claudication or absent pulses.
shown in Table 2. Mean BMI values ranged from 18.9 ±
1.6 kg/m2 for patients in the lowest BMI quintile to 34.7 ±
4.3 kg/m2 for patients in the highest BMI quintile. In gen-
eral, patients in the highest BMI quintile (BMI 30.0–75.2)
were younger, had fewer males and had a greater per-
centage of blacks and lower percentage of whites com-
pared with those in the lower BMI groups. Diabetes both
as a cause of ESRD and as a comorbid condition was
more common in the higher BMI groups. In contrast,
the prevalence of several cardiovascular conditions, in-
cluding coronary artery disease (23.4% vs. 25.1%), my-
ocardial infarction (7.6% vs. 8.7%), peripheral vascular
disease (12.7% vs. 15.6%) and cardiac arrest/arrythmia
(5.0% vs. 7.1%) were significantly lower in the highest
BMI quintile compared with the lowest BMI quintile.
Similarly, the prevalence of noncardiovascular comor-
bid indicators (chronic lung disease, alcohol dependence,
AIDS, and cancer) and measures of functional status
(inability to walk or transfer independently) were less
common among patients in highest BMI quintile. The
use of peritoneal dialysis as a primary treatment modal-
ity was greatest in the third and fourth quintile groups
(14.4% each) and least common in the first and fifth
groups (10.0% and 12.6%, respectively).
Deaths, transplants, and loss to follow-ups
The median follow-up was 12 months; 33,942 (25.2%)
patients died, 6855 (5.1%) were transplanted, and 4693
(3.5%) patients were lost to follow-up within the 2-year
period. Table 3 illustrates the unadjusted death fractions,
number of transplants, and loss to follow-ups for the en-
tire cohort stratified by diabetes and BMI quintile. In
general, the death rates decreased with increasing BMI
quintile for both peritoneal dialysis and hemodialysis-
treated patients; however, the magnitude of the decrease
was far greater in the hemodialysis-treated group. Among
diabetics, the unadjusted death rates were higher for
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Table 3. Deaths, transplants, and losses to follow-up for peritoneal dialysis and hemodialysis-treated patients by body mass index (BMI) quintile
(N = 134,728)
BMI-1 BMI-2 BMI-3 BMI-4 BMI-5
(8.8–20.9) (20.9–23.5) (23.5–26.1) (26.1–30.0) (30.0–75.2)
Number 27,197 26,691 26,860 27,020 26,960
Diabetic population
Deaths
Peritoneal dialysis 215 (28.6) 342 (26.8) 419 (28.0) 402 (25.4) 394 (25.0)
Hemodialysis 2,492 (36.4) 2,366 (30.0) 2,336 (26.2) 2,426 (23.7) 2,492 (21.1)
Transplants
Peritoneal dialysis 89 (11.8) 159 (12.5) 148 (9.9) 144 (9.1) 72 (4.6)
Hemodialysis 165 (2.4) 243 (3.1) 290 (3.3) 304 (3.0) 275 (2.3)
Lost-to-follow-up
Peritoneal dialysis 22 (2.9) 22 (1.7) 35 (2.3) 36 (2.3) 36 (2.3)
Hemodialysis 195 (2.9) 224 (2.8) 268 (3.0) 316 (3.1) 351 (3.0)
Nondiabetic population
Deaths
Peritoneal dialysis 519 (26.4) 465 (20.5) 435 (18.4) 390 (16.9) 315 (17.3)
Hemodialysis 5,820 (33.0) 4,011 (26.4) 3,369 (23.9) 2,664 (20.7) 2,070 (17.6)
Transplants
Peritoneal dialysis 237 (12.0) 289 (12.7) 321 (13.6) 310 (13.4) 212 (11.7)
Hemodialysis 621 (3.5) 793 (5.2) 804 (5.7) 757 (5.9) 622 (5.3)
Lost to follow-up
Peritoneal dialysis 56 (2.8) 88 (3.9) 55 (2.3) 71 (3.1) 56 (3.1)
Hemodialysis 723 (4.1) 574 (3.8) 569 (4.0) 512 (4.0) 484 (4.1)
Number of events (%).
hemodialysis compared with peritoneal dialysis–treated
patients in the first and second BMI quintile (36.4% vs.
28.6%, 30.0% vs. 26.8%). Contrastingly, death rates were
higher for peritoneal dialysis–treated patients in the third
to fifth BMI quintiles (28.0% vs. 26.2%, 25.4% vs. 23.7%,
and 21.1% vs. 25.0%, respectively). For, nondiabetics,
the unadjusted death rates were higher for hemodialy-
sis compared with peritoneal dialysis patients in all BMI
groups with the exception of the highest BMI quintile
where rates were equivalent.
Overall, transplantation rates were higher for peri-
toneal dialysis compared with hemodialysis-treated pa-
tients in both diabetic and nondiabetic groups. Among
peritoneal dialysis patients, transplantation rates were
essentially equivalent for all BMI quintiles in the non-
diabetic population (12.0%, 12.7%, 13.6%, 13.4%, and
11.7%, respectively); for diabetics, however, transplanta-
tion rates declined for patients in the in the highest three
BMI quintiles (9.9%, 9.1%, and 4.4%, respectively).
Among hemodialysis patients, transplantation rates var-
ied between 2.3% and 3.3% among BMI groups with dia-
betes and between 3.5% and 5.9% among groups without
diabetes.
The adjusted Cox survival curves for peritoneal dialysis
and hemodialysis-treated patients in each BMI category
as shown in Figures 1 to 5. For diabetic patients, survival
was significantly poorer for peritoneal dialysis compared
with hemodialysis in each of the highest three BMI quin-
tile groups (BMI-3 to BMI-5). The curves begin to diverge
between 6 and 10 months with the greatest separation oc-
curring for patients in the highest BMI quintile. In con-
trast, for nondiabetics, the treatment survival curves in
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Fig. 1. Adjusted Cox survival curves for new end-stage renal disease
(ESRD) patients treated with peritoneal dialysis versus hemodialysis
stratified by body mass index (BMI) quintile (<20.9 kg/m2). All mod-
els adjusted for age at study start, gender, race, hypertension, coronary
artery disease, cardiac arrest/arrhythmia, peripheral vascular and cere-
brovascular disease, congestive heart failure, tobacco use, chronic lung
disease, AIDS, neoplasm, alcohol dependence, serum albumin, hemat-
ocrit, estimated glomerular filtration rate, functional status (inability to
walk and transfer), and pre-ESRD erythropoietin use.
each BMI category were virtually superimposed with the
exception of the lowest BMI group where the curves be-
gin diverge at 18 to 20 months and the highest BMI group
with separation occurring at 20 months.
Relationship of BMI with mortality in peritoneal dialysis
and hemodialysis patients
The shape of the BMI mortality curves in each dialysis
group is demonstrated in Figures 6 and 7. Among dia-
betics who were treated with hemodialysis, the relative
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Fig. 2. Adjusted Cox survival curves for new end-stage renal disease
(ESRD) patients treated with peritoneal dialysis versus hemodialysis
stratified by body mass index (BMI) quintile (20.9–23.5 kg/m2).
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Fig. 3. Adjusted Cox survival curves for new end-stage renal disease
(ESRD) patients treated with peritoneal dialysis versus hemodialysis
stratified by body mass index (BMI) quintile (23.5–26.1 kg/m2).
risk of death was greatest for patients in the lowest BMI
quintile (BMI < 20.9; RR = 1.40, 95% CI 1.32–1.50) com-
pared with the referent (BMI 23.5–26.1; RR = 1.00) and
decreased with increasing body size such that patients
with a BMI >30.0 kg/m2 experienced the greatest ben-
efit (RR = 0.97, 95% CI 0.96–0.99). The BMI mortality
risk patterns for nondiabetics were virtually identical as
shown in Figure 6. Among diabetics treated with peri-
toneal dialysis, a higher risk of death was observed only
for patients with a BMI <20.9 kg/m2 (RR = 1.20, 95%
CI 1.01–1.43). No survival advantage or disadvantage was
found for patients for BMI values beyond this. For nondi-
abetics treated with peritoneal dialysis, the mortality risk
associations were similar.
Mortality risks of peritoneal dialysis and hemodialysis by
BMI in new ESRD patients: Intention-to-treat
The finding of an overall significant interaction be-
tween treatment modality, BMI, and survival as well as
treatment modality, diabetes and survival (P < 0.0001
for each) permitted us to investigate these relationships
further in a series of time-dependent Cox regression mod-
els stratified by diabetes and BMI quintile. The relation-
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Fig. 4. Adjusted Cox survival curves for new end-stage renal disease
(ESRD) patients treated with peritoneal dialysis versus hemodialysis
stratified by body mass index (BMI) quintile (26.1–30.0 kg/m2).
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Fig. 5. Adjusted Cox survival curves for new end-stage renal disease
(ESRD) patients treated with peritoneal dialysis versus hemodialysis
stratified by body mass index (BMI) quintile (>30.0 kg/m2).
ship between treatment modality and subsequent mor-
tality risk was explored for the entire cohort in each BMI
category and the adjusted hazard ratios with 95% CI are
presented in Table 4. Among diabetics, the hazard rates
did not differ significantly for patients treated with peri-
toneal dialysis or hemodialysis in the lowest two BMI
quintile groups (BMI-1 RR = 0.99, 95% CI 0.83–1.17,
and BMI-2 RR = 1.12, 95% CI 0.98–1.29). However, from
the third to the fifth BMI quintile, the relative mortality
risk was significantly higher by 26%, 15% and 44% for
peritoneal dialysis compared with hemodialysis patients,
respectively. In these three BMI quintiles, the mortal-
ity risk was significantly greater for peritoneal dialysis–
treated compared with hemodialysis-treated patients be-
tween 6 and 24 months of follow-up, the magnitude of
risk being greatest for peritoneal dialysis patients in the
highest BMI quintile (BMI-5; RR = 1.19, 1.72, 1.53, and
2.09, respectively, at each successive 6-month interval,
P < 0.001).
Among nondiabetics, the relative peritoneal dialysis/
hemodialysis hazard ratios over the 2-year period for
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Fig. 6. Relative risk of death by body mass
index (BMI) quintile for new end-stage re-
nal disease (ESRD) patients treated with
hemodialysis. All models adjusted for age at
study start, gender, race, hypertension, coro-
nary artery disease, cardiac arrest/arrhythmia,
peripheral vascular and cerebrovascular dis-
ease, congestive heart failure, tobacco use,
chronic lung disease, AIDS, neoplasm, alco-
hol dependence, serum albumin, hematocrit,
estimated glomerular filtration rate, func-
tional status (inability to walk and transfer),
and pre-ESRD erythropoietin use. ∗P < 0.05;
∗∗P < 0.01; ∗∗∗P < 0.001 compared to a rel-
ative risk of 1.00. Reference BMI 23.5–26.1
kg/m2.
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Fig. 7. Relative risk of death by body mass
index (BMI) quintile for new end-stage re-
nal disease (ESRD) patients treated with peri-
toneal dialysis. All models adjusted for age at
study start, gender, race, hypertension, coro-
nary artery disease, cardiac arrest/arrhythmia,
peripheral vascular and cerebrovascular dis-
ease, congestive heart failure, tobacco use,
chronic lung disease, AIDS, neoplasm, alco-
hol dependence, serum albumin, hematocrit,
estimated glomerular filtration rate, func-
tional status (inability to walk and transfer),
and pre-ESRD erythropoietin use. ∗P < 0.05;
∗∗P < 0.01; ∗∗∗P < 0.001 compared to a rel-
ative risk of 1.00. Reference BMI 23.5–26.1
kg/m2.
patients in the first to the fourth BMI quintile groups
were similar (RR = 1.07, 1.01, 0.96, and 1.04, respectively)
with only patients in the fifth BMI quintile experiencing a
higher mortality on peritoneal dialysis (RR = 1.22, 95%
CI 105, 1.41). Despite this the time-dependent regression
models demonstrated a trend of increasing hazard for
peritoneal dialysis compared with hemodialysis-treated
patients in the highest three BMI groups (BMI-3;
RR = 0.68, 1.13, 1.35, and 1.07; BMI-4; RR = 0.78, 1.08,
1.38, and 1.33; and BMI-5; RR = 0.93, 1.07, 1.36, and 1.49
at each successive 6-month interval, respectively). In ad-
dition, a significant race-modality interaction was found
with the mortality risks for whites with BMI values >
30.0 kg/m2 (RR peritoneal dialysis/hemodialysis = 1.28,
95%CI 1.08–1.51) being significantly greater than those
of nonwhites [RR peritoneal dialysis/hemodialysis =
1.01. 95% CI 0.74–1.37).
Mortality risks of peritoneal dialysis and hemodialysis
by BMI in new ESRD patients: As-treated analyses
The results of the time-dependent as-treated analyses
were similar to those of the intent-to-treat analysis and
are presented in Table 5. For diabetics whose BMI values
were in the third (23.5–26.1 kg/m2) and fifth (>30.0 kg/
m2) quintiles, the adjusted mortality risk was significantly
higher for patients who started on peritoneal dialysis PD
and remained on this therapy during follow-up (RR, peri-
toneal dialysisorig/hemodialysisorig = 1.16, 95% CI 1.02–
1.33 and RR = 1.45, 95% CI 1.28–1.64, respectively) and
tended to be higher for patients in the fourth BMI quin-
tile (RR, peritoneal dialysisorig/hemodialysisorig = 1.08,
95% CI 0.94–1.22). For diabetic patients who switched
therapy during follow-up, either from peritoneal dial-
ysis to hemodialysis (hemodialysisnew/hemodialysisorig)
or from hemodialysis to peritoneal dialysis (peritoneal
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Table 4. Relative risk of death in months for peritoneal dialysis versus hemodialysis among incident end-stage renal disease (ESRD) patients by
body mass index (BMI) in quintiles: Intent-to-treat analysis
Adjusted peritoneal dialysis/hemodialysis relative hazards ratios
BMI-1 BMI-2 BMI-3 BM1 - 4 BMI-5
(8.8–20.9) (20.9–23.5) (23.5–26.1) (26.1–30.0) (30.0–75.2)
Diabetic population
0–6 1.16 (0.93–1.44) 1.10 (0.90–1.34) 1.03 (0.84–1.25) 0.89 (0.73–1.08) 1.19 (0.98–1.44)
6–12 1.12 (0.87–1.45) 0.99 (0.79–1.24) 1.16 (0.95–1.42) 1.43 (1.19–1.71)a 1.72 (1.44–2.06)a
12–18 0.97 (0.71–1.33) 1.51 (1.21–1.89) 1.35 (1.08–1.68)b 1.49 (1.21–1.84)a 1.53 (1.24–1.89)a
18–24 1.33 (0.88–1.99) 1.16 (0.85–1.60) 1.58 (1.20–2.08)b 1.44 (1.10–1.89)b 2.09 (1.65–2.66)a
0–24 0.99 (0.83–1.17) 1.12 (0.98–1.29) 1.26 (1.13–1.43)b 1.15 (1.02–1.30)b 1.44 (1.27–1.63)a
Nondiabetic population
0–6 0.92 (0.78–1.09) 0.98 (0.82–1.16) 0.68 (0.55–0.84)a 0.78 (0.61–0.98) 0.93 (0.70–1.25)
6–12 1.02 (0.83–1.25) 0.99 (0.81–1.22) 1.13 (0.92–1.38) 1.08 (0.85–1.37) 1.07 (0.78–1.48)
12–18 1.08 (0.85–1.38) 0.96 (0.75–1.23) 1.35 (1.08–1.69)b 1.38 (1.05–1.80)c 1.36 (0.98–1.89)
18–24 1.47 (1.13–1.91) 1.07 (0.79–1.46) 1.07 (0.77–1.48) 1.33 (0.96–1.85) 1.49 (1.01–2.18)c
0–24 1.07 (0.96–1.19) 1.01 (0.90–1.13) 0.96 (0.85–1.08) 1.04 (0.91–1.18) 1.22 (1.05–1.41)b
aP < 0.001; bP < 0.01; cP < 0.05 compared to a relative risk of 1.00.
Table 5. Relative risk of death in months for peritoneal dialysis versus hemodialysis among incident end-stage renal disease (ESRD) patients by
body mass index (BMI) in quintiles: As-treated analysisa
Adjusted peritoneal dialysis/hemodialysis relative hazards ratios
BMI-1 BMI-2 BMI-3 BMI-4 BMI-5
(8.8–20.9) (20.9–23.5) (23.5–26.1) (26.1–30.0) (30.0–75.2)
Diabetic population
Hemodialysisorig 1.00 1.00 1.00 1.00 1.00
Peritoneal dialysisorig
0–6 1.21 (0.96–1.53) 1.30 (1.06–1.59)b 1.15 (0.94–1.42) 1.07 (0.87–1.31) 1.43 (1.17–1.75)c
6–12 1.31 (1.01–1.71)b 1.05 (0.82–1.35) 1.19 (0.95–1.49) 1.55 (1.26–1.90)c 2.09 (1.73–2.53)c
12–18 0.96 (0.67–1.38) 1.49 (1.16–1.93)d 1.54 (1.21–1.95)c 1.40 (1.10–1.79)d 1.72 (1.36–2.17)c
18–24 1.29 (0.81–2.06) 0.91 (0.61–1.38) 1.56 (1.12–2.16)d 1.37 (0.99–1.87) 2.25 (1.69–2.99)c
0–24 1.04 (0.88–1.23) 1.03 (0.89–1.19) 1.16 (1.02–1.33)b 1.08 (0.94–1.22) 1.45 (1.28–1.64)c
Peritoneal dialysis  hemodialysisnewe 1.03 (0.70–1.53) 1.73 (1.34–2.24)c 1.53 (1.20–1.95)c 1.95 (1.57–2.42)c 1.74 (1.39–2.18)c
Hemodialysis  peritoneal dialysisnewf 1.28 (0.97–1.69) 1.48 (1.12–1.95)d 1.57 (1.23–2.01)c 1.46 (1.13–1.89)c 2.04 (1.66–2.50)c
Nondiabetic population
Hemodialysisorig 1.00 1.00 1.00 1.00 1.00
Peritoneal dialysisorig
0–6 1.03 (0.87–1.22) 1.13 (0.94–1.35) 0.76 (0.60–0.96)b 0.88 (0.69–1.12) 1.14 (0.84–1.54)
6–12 1.12 (0.90–1.40) 1.07 (0.86–1.34) 1.28 (1.03–1.60)b 1.30 (1.01–1.67)b 1.32 (0.93–1.86)
12–18 0.91 (0.67–1.22) 0.89 (0.67–1.19) 1.34 (1.04–1.74)b 1.30 (0.95–1.79) 1.75 (1.22–2.51)d
18–24 1.21 (0.87–167) 0.99 (0.69–142) 0.97 (0.66–1.45) 1.35 (0.92–1.98) 1.76 (1.13–2.74)b
0–24 0.96 (0.85–1.09) 0.94 (0.82–1.07) 0.91 (0.79–1.05) 0.93 (0.79–1.09) 1.12 (0.92–1.36)
Peritoneal dialysis  hemodialysisnewe 1.63 (1.28–2.07)c 1.54 (1.19–2.00)c 1.32 (1.01–1.73) 1.25 (0.92–1.71) 1.12 (0.76–1.67)
Hemodialysis  peritoneal dialysisnewf 1.09 (0.86–1.38) 1.39 (1.10–1.75)d 1.23 (0.94–1.60) 1.40 (1.08–1.81)b 1.92 (1.43–2.57)c
orig, original modality.
aThe as-treated analyses compared the mortality risks of patients who switched from one modality to another during the follow-up with those remaining on
peritoneal dialysis (peritoneal dialysisorig) or hemodialysis (hemodialysisorig) since ESRD start; bP < 0.05; cP < 0.001; dP < 0.01 compared to a relative risk of 1.00;
eHemodialysisnew is patients who switched from peritoneal dialysis to hemodialysis; fperitoneal dialysisnew is patients who switched from hemodialysis to peritoneal
dialysis.
dialysisnew/hemodialysisorig) compared to those who
remained on hemodialysis, the relative hazards ratios
were significantly and substantially greater for all BMI
groups (with the exception of the lowest) independent of
the direction of switch.
For nondiabetics, a trend of increasing peritoneal dial-
ysis/hemodialysis hazard was seen only for patients with
BMI values in the highest three quintiles. The mortal-
ity patterns of patients who switched therapies during
follow-up were similar to those of diabetics with two ex-
ceptions. First, low BMI patients (BMI-1 and BMI-2)
who switched from peritoneal dialysis to hemodialysis
(hemodialysisnew) experienced a significantly 63% and
54% increased mortality compared with hemodialysisorig
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patients. Second, high BMI patients (BMI-4 and BMI-5)
who switched from hemodialysis to peritoneal dialysis
(peritoneal dialysisnew) experienced a significantly 40%
and 92% increased mortality compared with the referent.
Additional sensitivity analyses tested the robustness of
our observations. First, we repeated the regression anal-
yses in which we adjusted only for objective measures of
disease at ESRD onset, namely serum albumin, hemat-
ocrit, and residual renal function. Second, we considered
the possibility of selection bias due to differences in the
rates of renal transplantation between peritoneal dialysis
and hemodialysis groups, differences that may result in
“healthier” peritoneal dialysis patients receiving a renal
transplant while leaving a relatively “sicker” fraction on
peritoneal dialysis. In each additional analysis, the asso-
ciation of peritoneal dialysis with higher mortality risk
among large patients persisted (data not shown).
DISCUSSION
In this national cohort of United States dialysis pa-
tients, we demonstrate significant mortality differences
between peritoneal dialysis and hemodialysis that vary
according to body size. All else equal, the selection of
peritoneal dialysis over hemodialysis among new ESRD
patients with high BMI values was associated with signifi-
cantly increased mortality risks. Among diabetics, the risk
of death associated with peritoneal dialysis use became
significant when the BMI was at least 23.5 kg/m2 and was
greatest for patients with BMI > 30 kg/m2. Among non-
diabetics, the mortality patterns followed a similar trend
although less impressive with significantly higher mortal-
ity risk for peritoneal dialysis–treated patients with BMI
values > 30.0 kg/m2. These differences in mortality risk
between peritoneal dialysis and hemodialysis were not
constant over time but increased with duration of dialy-
sis. Moreover, they remained significant even after a com-
prehensive adjustment for confounding factors known to
differ between groups and differences in rates of re-
nal transplantation. Our findings suggest that the utiliza-
tion of peritoneal dialysis over hemodialysis among new
ESRD patients with large body habitus, especially dia-
betics, may adversely affect patient survival.
Although it has been suggested that peritoneal dialy-
sis and hemodialysis are relatively “equivalent” therapies
for most new ESRD patients who begin dialysis therapy
in the United States, recent studies have found important
differences between peritoneal dialysis and hemodialysis
in high-risk groups [5, 6]. The choice of peritoneal dial-
ysis over hemodialysis among patients with large body
habitus was associated with a survival disadvantage. For
diabetics these survival differences were seen in patients
with a BMI as low as 23.5 kg/m2 such that peritoneal dial-
ysis patients even with “average” BMI values (BMI-3;
23.5–26.1 kg/m2) experienced a 21% higher mortality
compared with similar hemodialysis patients. The risk of
death was even greater for obese patients (BMI > 30 kg/
m2) treated with peritoneal dialysis over hemodialysis.
Peritoneal dialysis–treated patients in the highest BMI
category experienced a 47% higher mortality. In con-
trast, overall survival was similar for peritoneal dialysis
and hemodialysis patients with BMI values < 23.5 kg/m2.
Despite the putative protective benefits of large body
size on survival, this study suggests that the utilization
of peritoneal dialysis over hemodialysis among large and
even moderately sized diabetic patients is associated with
higher death risk.
The mortality patterns of nondiabetics followed a sim-
ilar trend with increased hazard of death for larger
patients treated with peritoneal dialysis over hemodial-
ysis. In contrast to diabetic patients, however, it ap-
peared that the overall increased risk associated with
peritoneal dialysis use was present only for those in
the obese category (BMI >30 kg/m2). Notwithstand-
ing this, the time-dependent models (both the intent-to-
treat and as-treated) demonstrated a trend of increasing
hazard of death for peritoneal dialysis compared with
hemodialysis-treated patients with BMI values >26.1 kg/
m2. While the intent-to-teat model may be flawed as it
compares mortality rates according to the original modal-
ity assignment and ignores subsequent switches in ther-
apy from peritoneal dialysis to hemodialysis and vice
versa, we repeated the analysis using an as-treated ap-
proach. This ensured that treatment comparisons were
based entirely on the actual treatment each patient re-
ceived during the follow-up period.
The question of whether obesity confers a survival ad-
vantage or indeed disadvantage in specific dialysis pop-
ulations has been addressed in several recent studies
[12–15, 18, 19]. Among hemodialysis patients the evi-
dence is strongly suggestive of a protective effect such
that patients with the largest body size have the low-
est mortality risk [12, 14]. In contrast, studies that have
addressed this subject in peritoneal dialysis–treated pa-
tients have yielded conflicting results. Johnson et al [18]
in a cohort of 43 peritoneal dialysis patients followed for
3 years found a significantly lower risk of death among
those with those with a BMI >27.5 kg/m2 compared with
the control group (BMI of 20.0–27.5 kg/m2) while Aslam
et al [19] failed to show any association between BMI
and survival among a substantially larger incident peri-
toneal dialysis cohort followed for 2 years. In our study
we have overcome several of the limitations inherent in
these reported studies, including small sample size, cen-
ter effect, and the possibility of confounding by unmea-
sured comorbidity. We demonstrate that increasing BMI
is associated with improved survival among new ESRD
patients who are treated with hemodialysis, a finding that
was not paralleled in peritoneal dialysis–treated subjects.
Moreover, we have shown that these translate into a
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favorable advantage for larger patients who are treated
with hemodialysis over peritoneal dialysis.
While it is unclear how obesity may preferentially in-
crease the relative mortality hazard of peritoneal dial-
ysis over hemodialysis, there are several possibilities.
First, dialysis adequacy is a concern among all ESRD
patients with high BMI irrespective of modality assign-
ment [9–11]. Overweight hemodialysis patients are less
likely to receive the minimum recommended dialysis and
are underdialyzed compared with normal weight patients.
Moreover, underdialysis in overweight hemodialysis pa-
tients is associated with a significant reduction in survival
[11]. Overweight patients treated with peritoneal dialysis
may experience similar difficulties in achieving weekly
creatinine clearances and Kt/Vurea targets considered ad-
equate by the K/DOQI guidelines. Indeed, Jensen et al [9]
have predicted that peritoneal dialysis patients weighing
more than 80 kg cannot receive adequate dialysis even
with four 3 L continuous ambulatory peritoneal dialy-
sis (CAPD) exchanges daily. This may become especially
apparent when residual renal function declines over time
resulting in a substantial reduction of renal Kt/Vurea. It
is possible that failure to achieve adequate dialysis tar-
gets in large patients treated with peritoneal dialysis is
more detrimental to survival than in patients treated with
hemodialysis. Second, fluid balance may be more difficult
to assess and manage in obese patients maintained on
peritoneal dialysis as compared with hemodialysis. More-
over, fluid control may be further compromised by the
gradual loss of residual renal function and urine volume
over time among patients with large body habitus and
may explain in part at least the deleterious effect of peri-
toneal dialysis on survival [20–22]. The recent ADEMEX
clinical trial would support the hypothesis that declining
residual renal function, and not peritoneal clearance, may
be the primary determinant of poor survival among large
peritoneal dialysis patients [23, 24]. Indeed the known
rates of decline in residual renal function that are ob-
served in peritoneal dialysis–treated patients would be
consistent with the observed temporal increases in mor-
tality in our study. Finally, it is also possible that several
other factors not accounted for in this analysis could mod-
ify the BMI-modality relationship. Differences in rates of
infection, cardiovascular disease, or specific differences
in aspects of delivered clinical care between large peri-
toneal dialysis and hemodialysis might be responsible for
the observed mortality differences.
Despite our efforts to provide unbiased comparisons
and there are inherent limitations to the present study.
First, selection bias is a potential obstacle to mortal-
ity comparisons of this nature as the characteristics of
peritoneal dialysis and hemodialysis-treated patients at
ESRD onset may differ considerably [25–28]. To over-
come this we have adjusted for a comprehensive list
of sociodemographic characteristics, 18 comorbid indi-
cators including a measure of functional status and an
index of pre-ESRD care recorded at baseline. Second,
we have carefully considered the issue of patients switch-
ing from one modality to another during follow-up and
the fact that peritoneal dialysis and hemodialysis do not
demonstrate constant hazard rates over time. Thus, our
observations are based on both “intent-to treat” as well
as “as-treated” analyses thereby reducing bias resulting
from switches in treatment modalities during follow-up.
Third, our analyses are based on a nationally representa-
tive sample of new ESRD patients in the United States
thereby enhancing generalizability and limiting survival
bias with the use of “prevalent” cohorts. It should be
noted, however, that these observations might not be
valid in countries that record greater utilization and over-
all better outcomes on peritoneal dialysis. Finally, the op-
timal study design for comparing peritoneal dialysis and
hemodialysis treatment modalities would be a random-
ized controlled clinical trial, this has not been possible to
date due to the logistic, feasibility, methodologic, and fi-
nancial concerns in designing and executing such a study
[29, 30]. In its absence, the current nonrandomized obser-
vational approach provides the best alternative scientific
approach.
An additional concern in our study relates to the re-
liability of the BMI measure from the CMS Medical
Evidence Document. BMI was estimated from patient’s
height and dry weight recorded at the time of ESRD ini-
tiation. It is possible that not all patients were at their
true dry weight by the time the CMS form was signed as
the majority (93%) had been on dialysis for ≤1 month or
less. This could lead to an overestimation of the BMI
(weight in kg/height in m2) and potentially bias com-
parisons between dialysis groups. However, any inaccu-
racy in the estimate of BMI that results from this effect
will be of a similar size and will be in the same direc-
tion (overestimation) across all baseline BMI quintile
groups, from lowest to highest. Finally, we submit that our
study lacked prospective data on residual renal function,
delivered dose of dialysis, anemia management, nutri-
tional indices, and other clinical indicators that may have
varied with treatment modality and time and influenced
survival outcome. Such factors should be included in fu-
ture mortality comparisons in order to provide mecha-
nistic insights into the reported survival differences.
CONCLUSION
This study demonstrates that large patients who are
new to ESRD in the United States have significantly
poorer survival when treated with peritoneal dialysis as
compared with hemodialysis. This observation was espe-
cially apparent in diabetic patients with BMI > 23.5 kg/m2
and non-diabetics with a BMI >30.0 kg/m2. We also
show that the negative impact of peritoneal dialysis on
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survival is time-dependent phenomenon with increased
relative mortality risk occurring with longer follow-up.
While concern must always be expressed for the poten-
tial for confounding on these mortality analyses based
on a non-randomized study design, the comprehensive
adjustment for measured sociodemographic, comorbid,
and functional status indicators reduces this possibility
and suggests the presence of a true treatment difference.
Our study does not provide any mechanistic insight into
the reasons for these survival differences; however, inad-
equate dialysis among large peritoneal dialysis patients
is a strong contender. Taken together, these findings sug-
gest that peritoneal dialysis, as is currently practiced in the
United States, is inferior to hemodialysis for new ESRD
patients with large body habitus. In the light of recent
evidence, we suggest that greater efforts be expended in
improving the delivery of dialysis to all large patients re-
ceiving dialysis in the United States especially those re-
ceiving peritoneal dialysis.
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